相关实验视频

Updated: Jul 24, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

对直肠癌的短期放射治疗:阿根廷的现实世界证据

Natalia S Tissera^1,2, Berenice Freile^3,4, Federico Waisberg^3,5

¹Upper Gastrointestinal Cancer Translational Research Group, Vall´d Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.

Ecancermedicalscience

|July 3, 2023

概括

短疗程放射治疗 (SCRT) 对直肠癌有效,可在某些局部晚期病例中进行非手术治疗,并在转移性疾病中提供局部控制. 需要进一步的前性研究来证实这些发现.

科学领域:

在瘤学瘤学.
辐射瘤学辐射瘤学
胃肠道瘤学胃肠道瘤学

背景情况:

短期放射治疗 (SCRT) 是一种标准的新辅助治疗,用于切除局部晚期直肠癌 (LARC) 和转移性直肠癌的局部控制.
关于非手术治疗的患者使用SCRT的数据有限.

研究的目的:

描述接受SCRT治疗LARC和转移性直肠癌的患者.
根据SCRT评估毒性和治疗后管理策略.

主要方法:

在2014年3月至2022年6月期间,44名用SCRT治疗的直肠癌患者的回顾性分析.
收集了关于患者人口统计,疾病阶段,治疗序列 (化疗SCRT),临床完整反应 (cCR) 和不良事件 (AE) 的数据.

主要成果:

大多数患者是男性 (66%),平均年龄为59岁. 第四期疾病 (59.1%) 和LARC (40.9%) 是常见的. 临床完整反应 (cCR) 在18.2%的患者中发生.
在LARC中,SCRT之后的巩固化疗是常见的 (89%). 在转移性疾病中,SCRT随后的巩固化疗也很常见 (53.8%).
与SCRT前的诱导化疗相比,当SCRT遵循巩固化疗时,不良事件的发生率更高 (36.7%与25%相比,p=0.02).

结论:

随着化疗后的SCRT可以允许在LARC患者中忽略手术,实现cCR,与以前的研究相比,局部复发率相似.
在IV期直肠癌中,SCRT是局部疾病控制的可行选择,具有低毒性的直肠癌.
多学科团队的决策和前性研究对于优化SCRT使用至关重要.

关键词:

拉丁美洲拉丁美洲拉丁美洲临床完整反应的临床完整反应这是直肠癌.短时间的放射疗法.观察和等待,等待和等待.

更多相关视频

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Published on: October 6, 2023

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...